FDA Shortens Clinical Trial Timelines for Drugs and Medical Devices with AI
Summary
The FDA launches a pilot program using Causal AI to shorten clinical trial timelines for drugs and medical devices, potentially reducing trial duration by 20-40% and speeding regulatory approval.
Similar Articles
AI is accelerating drug development
AI is transforming U.S. pharmaceutical R&D by accelerating drug discovery, preclinical testing, clinical trials, and regulatory review, with early evidence suggesting it could cut development times by roughly half and reduce costs.
The Current State Of FDA-Approved AI-Enabled Medical Devices.
This article provides an overview of the current landscape of AI-enabled medical devices that have received FDA approval, highlighting trends and regulatory progress in healthcare technology.
How AI helps scientists design the next generation of medicines
AI is accelerating biologic drug design by predicting candidate molecules and enabling multi-target therapies, with potential to cut discovery timelines by 50% and target previously undruggable diseases.
Anthropic launches AI drug discovery program, joining tech giants in betting on healthcare (3 minute read)
Anthropic is launching an internal AI drug discovery program to develop treatments for neglected diseases, aiming to improve its AI tools for drugmakers and join tech giants in the healthcare market.
Trends in AI and Human-AI Interaction in Clinical Trials -- A Hybrid Human-AI Exploration
This paper analyzes temporal and geographical trends in AI terminology in clinical trials from clinicaltrials.gov, using a hybrid human-AI approach with GPT-5.5. It finds increasing AI-related trials, with China and the US leading, and discusses the viability of hybrid screening for human-AI interaction classification.